Although our transcriptomic search did not retrieve studies focusing on these pathways, many anti-obesity drugs target GPCRs and peptide hormones (e.g., GLP-1R/GIPR dual agonists). The gene discussed is GIPR; the disease is obesity due to melanocortin 4 receptor deficiency.